Propanc Biopharma faces Nasdaq delisting over minimum bid price violation
PPCB•Propanc Biopharma received a Nasdaq delisting notice after its closing bids remained below the $1 minimum for 30 consecutive business days. The company intends to appeal by October 30, which would stay delisting pending a hearings panel decision.
1. Delisting notice
Propanc Biopharma received Nasdaq’s delisting notice on October 23, 2026, after its common stock failed to meet the $1 minimum bid price for 30 consecutive business days before October 21. Its securities face delisting on November 2 unless the company requests an appeal.
2. Appeal plans
A reverse stock split within the prior year makes Propanc ineligible for the usual 180-calendar-day compliance period. Management intends to appeal by October 30; an appeal would stay delisting pending a hearings panel decision. The company believes it cured the bid-price deficiency after receiving the notice.
3. Potential effects
The company said delisting could reduce stock liquidity and constrain equity financing.
